The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
Open accessAbstract
UNLABELLED: Our purpose was to evaluate the safety and efficacy of (68)Ga-DOTATATE PET/CT compared with (111)In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and gastroenteropancreatic neuroendocrine tumors. METHODS: (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were obtained for 78 of 97 consecutively enrolled patients with known or suspected pulmonary or gastroenteropancreatic neuroendocrine tumors. Safety and toxicity were measured by comparing vital signs, serum chemistry values, or acquisition-related medical complications before and after (68)Ga-DOTATATE injection. Added value was determined by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were added to all prior imaging, including (111)In-pentetreotide. Interobserver reproducibility of (68)Ga-DOTATATE PET/CT scan interpretation was measured between blinded and nonblinded interpreters. RESULTS: (68)Ga-DOTATATE PET/CT and (111)In-pentetreotide scans were significantly different in impact on treatment (P < 0.001). (68)Ga-DOTATATE PET/CT combined with CT or liver MRI changed care in 28 of 78 (36%) patients. Interobserver agreement between blinded and nonblinded interpreters was high. No participant had a trial-related event requiring treatment. Mild, transient events were tachycardia in 1, alanine transaminase elevation in 1, and hyperglycemia in 2 participants. No clinically significant arrhythmias occurred. (68)Ga-DOTATATE PET/CT correctly identified 3 patients for peptide-receptor radiotherapy incorrectly classified by (111)In-pentetreotide. CONCLUSION: (68)Ga-DOTATATE PET/CT was equivalent or superior to (111)In-pentetreotide imaging in all 78 patients. No adverse events requiring treatment were observed. (68)Ga-DOTATATE PET/CT changed treatment in 36% of participants. Given the lack of significant toxicity, lower radiation exposure, and improved accuracy compared with (111)In-pentetreotide, (68)Ga-DOTATATE imaging should be used instead of (111)In-pentetreotide imaging where available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
Kumbasar, B., Kamel, I. R., Tekes, A., Eng, J., Fishman, E. K., & Wahl, R. L. (2004) · Abdominal Imaging · doi:10.1007/s00261-003-0162-3 · Cited by 84
Cited by
Fendler, W. P., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M. B., Okamoto, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0096 · Cited by 779
Howe, J. R., Cardona, K., Fraker, D. L., Kebebew, E., Untch, B. R., Wang, Y.-Z., Law, C. H., Liu, E. H., Kim, M. K., Menda, Y., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000846 · Cited by 376
Self-citationStrosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
Self-citationDeppen, S. A., Blume, J., Bobbey, A. J., Shah, C., Graham, M. M., Lee, P., Delbeke, D., & Walker, R. C. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165803 · Cited by 264
Self-citation
Metadata
- Authors
- Deppen, S. A., Liu, E., Blume, J. D., Clanton, J., Shi, C., Jones-Jackson, L. B., Lakhani, V., Baum, R. P., Berlin, J., Smith, G. T., Graham, M., Sandler, M. P., Delbeke, D., & Walker, R. C.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-01-14
- Volume
- 57
- Issue
- 5
- Pages
- 708-714
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2343075275
- Cited by
- 236
- References
- 2
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. https://app.cochat.ai/papers/10.2967/jnumed.115.163865
- The paper
- Deppen, S. A., Liu, E., Blume, J. D., Clanton, J., Shi, C., Jones-Jackson, L. B., Lakhani, V., Baum, R. P., Berlin, J., Smith, G. T., Graham, M., Sandler, M. P., Delbeke, D., & Walker, R. C. (2016). Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.115.163865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.